WO2003092589A2 - Salt solution for colon cleansing - Google Patents

Salt solution for colon cleansing Download PDF

Info

Publication number
WO2003092589A2
WO2003092589A2 PCT/US2003/013133 US0313133W WO03092589A2 WO 2003092589 A2 WO2003092589 A2 WO 2003092589A2 US 0313133 W US0313133 W US 0313133W WO 03092589 A2 WO03092589 A2 WO 03092589A2
Authority
WO
WIPO (PCT)
Prior art keywords
grams
composition
effective amount
purgation
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/013133
Other languages
English (en)
French (fr)
Other versions
WO2003092589A3 (en
Inventor
Mark Vb. Cleveland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Braintree Laboratories Inc
Original Assignee
Braintree Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29249548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003092589(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2484303A priority Critical patent/CA2484303C/en
Application filed by Braintree Laboratories Inc filed Critical Braintree Laboratories Inc
Priority to SI200331799T priority patent/SI1499331T1/sl
Priority to AT03724291T priority patent/ATE457172T1/de
Priority to DK03724291.4T priority patent/DK1499331T3/da
Priority to EP03724291A priority patent/EP1499331B1/en
Priority to JP2004500774A priority patent/JP2005530743A/ja
Priority to AU2003231160A priority patent/AU2003231160B2/en
Priority to DE60331220T priority patent/DE60331220D1/de
Publication of WO2003092589A2 publication Critical patent/WO2003092589A2/en
Publication of WO2003092589A3 publication Critical patent/WO2003092589A3/en
Anticipated expiration legal-status Critical
Priority to BE2013C049C priority patent/BE2013C049I2/fr
Priority to FR13C0055C priority patent/FR13C0055I2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Definitions

  • This formulation is effective to produce colonic purging to prepare the colon for surgical or diagnostic procedures and surprisingly does not cause clinically significant changes in electrolyte balance.
  • sigmoidoscopy In sigmoidoscopy, colonoscopy, radiographic examination, preparation for patients undergoing bowel surgery, and other medical or diagnostic procedures on the colon, it is important that the colon be thoroughly purged and cleaned. In particular, it is essential that as much fecal matter as possible be removed from the colon to permit adequate visualization of the intestinal mucosa. This is important prior to, for example, diagnositc procedures such as flexible sigmoidoscopy or colonoscopy, diagnostic examinations widely performed to screen patients for diseases of the colon. In addition, it is important that the intestines be cleansed thoroughly in order to obtain satisfactory radiographs of the colon. The same condition also applies when the colon is preopera- tively prepared for surgery, where removal of fecal waste materials is critically important for patient safety.
  • compositions have been developed for use as gastrointestinal washes for diagnostic purposes or for use as cathartic laxatives.
  • Such orally administered preparations are usually formulated as dilute or isotonic solutions of electrolytes such as sodium sulfate, sodium bicarbonate, sodium chloride and potassium chloride. These orally administered compositions are useful in the rapid cleansing of the colon for diagnostic purposes.
  • These formulations may include other agents such as polyethylene glycol.
  • These formulations have generally been administered in a quantity of about four liters as isotonic solutions'.
  • Go- LYTELY® formulated according to the following: polyethylene glycol 59 g, sodium sulfate 5.68 g, sodium bicarbonate 1.69 g, sodium chloride 1.46 g, potassium chloride 0.745 g and water to make up one liter (Davis et al. Gastroenterology 1980;78:991- 995).
  • Sodium sulfate and phosphate salts have been used as laxatives when diluted in a small volume (-300 mL) concentrated solution and taken in tablespoon sized (15ml) daily doses.
  • An example of this use is Glauber's Salt's (containing sodium sulfate).
  • Glauber's Salt's containing sodium sulfate.
  • these small volume preparations do not contain polyethylene glycol.
  • Sodium sulfate combined with polyethylene glycol and various other salts, administered in large volumes (1 gallon) over a short period of time is an effective gastrointestinal lavage, which cleanses the colon prior to colonoscopy or surgical procedures as described above.
  • aqueous phosphate salt concentrate produces a tremendous osmotic effect on the intra-luminal contents of the bowel and therefore, evacuation of the bowel occurs with a large influx of water and electrolytes into the colon from the body.
  • These phosphate salt preparations have been developed for the purpose of decreasing the volume required in colonic purgations.
  • One such preparation basically is comprised of 480 grams per liter monobasic sodium phosphate and 180 grams per liter dibasic sodium phosphate in stabilized buffered aqueous solution and is sold under the brand name Fleets Phospho-Soda.TM.
  • the isotonic solutions while not causing clinically significant fluid or electrolyte shifts, are, of necessity, of large volume, and difficult for patient ingestion.
  • the hypertonic solutions or 0 concentrated non-aqueous formulations are sometimes inadequate to prepare the colon and more importantly, can cause clinically significant electrolyte and fluid shifts, which have been known to cause deaths.
  • it is desirable to have a small volume orally administered colonic purgative formulation which may be easily and conveniently administered and which avoids the clinically significant problems and objectionable tastes s of known formulations. It can also be seen that it is desirable to have such a purgative formulation which may be administered without the large volumes necessary in conventional formulations and which avoids other potentially irritant chemicals or chemicals which could effect osmolality.
  • One purpose of the present research was to de- s velop a safe, effective, and well tolerated small volume solution made up of a high concentration of poorly absorbable salts that induce a colon cleansing catharsis after oral ingestion without clinically significant alternation of sodium, chloride, bicarbonate, potassium, calcium, and phosphate level and balance or other untoward effects on the recipient.
  • the disclosed colonic purgative formulations provide safe and effective purgative activity at lower dosages of salt than prior art sodium phosphate tablets, solutions of phosphates and sulfates, or combinations thereof.
  • a lower volume of fluid is ingested and there are no clinically significant changes in body electrolyte chemistry.
  • This colonic purgative can be administered with a minimum amount of patient discomfort and is better tolerated than prior art purgatives.
  • the colonic purgative may include an effective amount of one or more sulfate salts, Na 2 SO , MgSO 4 , and K 2 SO 4 have been used.
  • Polyethylene glycol may also be advantageously added to the colonic purgative composition.
  • hypertonic sodium phosphate solutions are also efficacious in cleansing the colon.
  • use of hypertonic sodium phosphate has been shown to cause upset in electrolyte balance including: hyperphosphatemia, hypocalcemia, positive so- dium balance, and negative potassium balance.
  • the average serum phosphate concentration rose from 2.8 to 6.5 mg/dL (Kolts et al., Am. J. Gastroenterology, 88:1218-1223, 1993), and in another some patients developed serum phosphate concentrations as high as 11.6 mg/dL (Nanner et al., Am. J. Gastroenterology 85:422-427, 1990).
  • the normal range for serum phosphate is generally con- sidered to be 2.6 to 4.5 mg/dL. Also, serum potassium fell to as low as 2.9 mEq/L, while the normal range is 3.4 to 5.4.
  • the Ca x P product rose from 35 to as high as 104, while the normal range is generally 22-47 (DiPalma et al., Digestive Diseases and Sciences, 41:749-753, 1996).
  • Hypertonic phosphate gastrointestinal cleansing solutions have also been associated with hypokalemia and hypocalcemia in some patients, resulting in serious injury and even death (Ahmed et al. Am. J. Gastro. 1998;91:1261-1262).
  • sulfate salts that omit phosphates (which are avidly absorbed) can be effective to produce colonic purgation.
  • formulations comprising effective amounts of one or more of the following sulfate salts ⁇ a 2 SO , MgSO 4 , and K 2 SO are effective.
  • Dosage amounts of Na 2 So 4 from about 0.01 g to about 40.0 g can be effective to produce purgation.
  • Doses of from about 0.1 g to about 20.0 g may be advantageously used.
  • Dosages of 1.0 to 10.0 g may be preferred.
  • Dosage amounts of MgSO 4 from about 0.01 g to about 40.0 g can be effective to produce purgation.
  • Doses of from about 0.1 g to about 20.0 g may be advantageously used. Dosages of 1.0 to 10.0 g may be preferred. Dosage amounts of K 2 SO from about 0.01 g to about 20.0 g can be effective to produce purgation. Doses of from about 0.1 g to about 10.0 g may
  • PEG polyethylene glycol
  • the above mixture of salts can be dissolved in a convenient volume of water.
  • a volume of less than one liter of water is well tolerated by most patients.
  • the mixture can be dissolved in any volume of water, and volumes of between 100 and 500 ml are often convenient. Any volume may be administered.
  • the effective dose may be divided and administered, to the patient in two, or more administrations over an appropriate time period. Generally, 2 doses administered of equal portions of the effective dose, separated by 6 to 24 hours produce satisfactory purgation
  • Clear liquids included strained fruit juices without pulp (apple, white grape, lemonade), water, clear broth or bouillon, coffee or tea (without milk or non-dairy creamer), carbonated and non-carbonated soft drinks, Kool-Aid® (or other fruit flavored drinks), Jell-O® gelatin (without added fruits or toppings), and ice Pop-
  • the concentration of the salts expressed in millequivalents was:
  • Solution E also contained 34g of Polyethylene glycol (PEG). Observations and Measurements:
  • Body weight was measured at 6:45 p.m. on day 1, and at noon on day 2.
  • Blood pressure (lying and after standing for 30 seconds) was measured every two hours, starting at 6:45 p.m. on day 1 and finishing at 11:45 a.m. on day 2.
  • Blood was drawn at 6:45 p.m. on day 1 and at 6 a.m., 8 a.m., 10 a.m. and 12 noon on day 2.
  • Blood was analyzed for calcium, sulfate, magnesium, phosphate, sodium, chloride, potassium, bicarbonate, osmolality, albumin, total protein, BUN, creatinine, and hematocrit.
  • Each stool was quantitatively collected in separate containers and its weight and consistency were measured.
  • Urine was quantitatively collected from 6 a.m. until 6 p.m. on day 1 (prior to ingestion of salts), from 7 p.m. on day 1 until 5 a.m. on day 2, and from 5 a.m. on day 2 until 12 noon on day 2. Urine was analyzed for sulfate, phosphate, calcium, magnesium and monovalent electrolytes. Results
  • Solution A contained 100 mmoles of Na 2 SO 4 and 100 mmoles of MgSO 4 , as well as small amounts of KC1 and KHCO 3 to replace anticipated K, Cl, and HCO 3 losses.
  • stool output (1500) was short of the Phospho- Soda output benchmark (2403 ml).
  • Solution D contained 142.5 mmoles of bothNa 2 SO 4 and MgSO 4 , and 23.75 mmoles of K 2 SO 4 . This solution resulted in a stool volume of 2202 mL, which was slightly (180 mL) short of benchmark. Electrolyte changes were clinically insignificant with this formulation. A further increase in the ingested amounts of salts would likely be effective but, we were concerned about taste problems.
  • solution E PEG 3350 was added and the K 2 SO content reduced slightly as compared to solution D.
  • solution E produced an average fecal output that slightly exceeded the Phospho-Soda benchmark, and the taste was acceptable.
  • This solution caused no increase in Ca x P product, and its effect on potassium balance ap- peared to be close to zero.
  • the absorption of sulfate after ingestion of solution E was 165 mEq, or 27% of the ingested load. However, the serum sulfate concentration remained well below the s level at which calcium sulfate precipitates form, therefore calcium levels remained unchanged. The absorption of magnesium after ingestion of solution E was 66 mEq, or 23% of the ingested load.
  • the second method that can be used involves changes in urine output of the solutes.
  • Solution E contains three sulfate salts (Na 2 SO 4 , K 2 SO 4 and MgSO 4 ) as well as polyethylene glycol. Sulfate, magnesium and polyethylene glycol are poorly absorbed, and ingestion of this solution therefore induces osmotic diarrhea.
  • the sodium content of solution E is less than the sodium content of Phospho-Soda, and solution E contains 0 potassium whereas Phospho-Soda does not.
  • Solution E and Fleet Phospho-Soda appear to provide equivalent colonic cleansing.
  • solu- tion E does not cause serum phosphate concentration to rise and does not cause a net gastrointestinal loss of potassium.
  • Phopho-Soda phosphate solution and solutions D and E produce similar volumes of osmotic diarrhea, and the quality of colon cleansing (as judged by examination of fecal fluid) with the two solutions were similar.
  • both solutions will be associated with some residual colonic fluid, which is not a problem during co- lonoscopy since such fluid is readily aspirated via the suction lumen of the colono- scope.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
PCT/US2003/013133 2002-04-30 2003-04-28 Salt solution for colon cleansing Ceased WO2003092589A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2003231160A AU2003231160B2 (en) 2002-04-30 2003-04-28 Salt solution for colon cleansing
JP2004500774A JP2005530743A (ja) 2002-04-30 2003-04-28 結腸の洗浄のための塩溶液
SI200331799T SI1499331T1 (sl) 2002-04-30 2003-04-28 Solna raztopina za čiščenje kolona
AT03724291T ATE457172T1 (de) 2002-04-30 2003-04-28 Salzlösung für die kolonreinigung
DK03724291.4T DK1499331T3 (da) 2002-04-30 2003-04-28 Saltopløsning til kolonrensning
EP03724291A EP1499331B1 (en) 2002-04-30 2003-04-28 Salt solution for colon cleansing
DE60331220T DE60331220D1 (de) 2002-04-30 2003-04-28 Salzlösung für die kolonreinigung
CA2484303A CA2484303C (en) 2002-04-30 2003-04-28 Salt solution for colon cleansing
BE2013C049C BE2013C049I2 (enExample) 2002-04-30 2013-07-17
FR13C0055C FR13C0055I2 (fr) 2002-04-30 2013-09-25 Solution saline pour le nettoyage du colon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/135,857 US6946149B2 (en) 2002-04-30 2002-04-30 Salt solution for colon cleansing
US10/135,857 2002-04-30

Publications (2)

Publication Number Publication Date
WO2003092589A2 true WO2003092589A2 (en) 2003-11-13
WO2003092589A3 WO2003092589A3 (en) 2004-02-05

Family

ID=29249548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013133 Ceased WO2003092589A2 (en) 2002-04-30 2003-04-28 Salt solution for colon cleansing

Country Status (15)

Country Link
US (1) US6946149B2 (enExample)
EP (3) EP1499331B1 (enExample)
JP (1) JP2005530743A (enExample)
AT (2) ATE528011T1 (enExample)
AU (1) AU2003231160B2 (enExample)
BE (1) BE2013C049I2 (enExample)
CA (1) CA2484303C (enExample)
CY (3) CY1110011T1 (enExample)
DE (1) DE60331220D1 (enExample)
DK (3) DK2292244T3 (enExample)
ES (3) ES2441890T3 (enExample)
FR (1) FR13C0055I2 (enExample)
PT (3) PT2233147E (enExample)
SI (3) SI2292244T1 (enExample)
WO (1) WO2003092589A2 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049049A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
WO2005051361A1 (en) * 2003-11-19 2005-06-09 Inkine Pharmaceutical Company, Inc. Colonic purgative composition with soluble binding agent
DE102005041711A1 (de) * 2005-09-01 2007-03-08 Kappstein, Ines, Prof. Dr.med. Darmspüllösung/Darmspülpulver
WO2007085676A1 (es) * 2006-01-30 2007-08-02 Laboratorios Casen-Fleet, S.L. Procedimiento de fabricación de una solución a base de polietilenglicol con electrolitos, producto obtenido y uso
US7658914B2 (en) 2002-10-25 2010-02-09 Norgine Bv Colon cleansing compositions
US9468686B2 (en) 2009-07-30 2016-10-18 Norgine Bv Solutions comprising polyethylene glycol and electrolytes
AU2015221520B2 (en) * 2003-11-19 2017-06-08 Salix Pharmaceuticals, Inc. Colonic purgative composition with soluble binding agent
US9919007B2 (en) 2013-03-15 2018-03-20 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
US12239659B2 (en) 2023-06-15 2025-03-04 Braintree Laboratories, Inc. Methods of administering safe colon cleansing compositions

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US20060051428A1 (en) * 2004-09-03 2006-03-09 Nelson Ayala Aspartame and citrate flavored phosphate salt laxative
US8061269B2 (en) 2008-05-14 2011-11-22 S.C. Johnson & Son, Inc. Multilayer stencils for applying a design to a surface
US8557758B2 (en) 2005-06-07 2013-10-15 S.C. Johnson & Son, Inc. Devices for applying a colorant to a surface
US7495063B2 (en) * 2006-02-03 2009-02-24 Dow Global Technologies Inc. Reduced oligomer concentration in high purity polyalkylene glycols
US7985429B2 (en) 2006-03-03 2011-07-26 C. B. Fleet Company, Inc. Flavored colonic cleansing system
US7998510B2 (en) * 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
USD683210S1 (en) 2007-03-01 2013-05-28 C.B. Fleet Company, Inc. Container for colonic cleansing kit
US20090053304A1 (en) * 2007-08-23 2009-02-26 Jinling Chen Composition and method of producing a taste masking formulation of laxatives for bowel cleaning preparation prior to colonoscopy
EP2234482B1 (en) * 2008-01-16 2015-08-05 Braintree Laboratories, Inc. Sulfate salt prophylaxis and therapies
DE102008035542A1 (de) 2008-07-30 2010-02-04 Siemens Aktiengesellschaft Verfahren zur Ermittlung von Messdaten aus dem Magen eines Patienten
US8778306B2 (en) * 2009-04-21 2014-07-15 Dale R. Bachwich Colon lavage system
KR20130100323A (ko) * 2010-10-08 2013-09-10 아지노모토 가부시키가이샤 Ｃｔ 콜로노그래피에 사용되는 경구 투여용 액제 및 소화관 조영용 조성물
PL2651415T3 (pl) 2010-12-13 2021-04-19 Rite-Prep Pty Ltd. Formulacje dożołądkowe i dookrężnicze oraz sposoby ich wytwarzania i zastosowania
CN105963701A (zh) 2011-01-28 2016-09-28 布伦特里实验室有限公司 用于肠道清洁的方法、组合物以及包装
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
DK2696690T3 (en) * 2011-04-15 2018-01-15 Braintree Laboratories Inc SULPHATE SALTS TO IMPROVE TRANSIT TIME
WO2013043828A1 (en) 2011-09-20 2013-03-28 Grain Processing Corporation Microspheres
CN102652759B (zh) * 2012-05-21 2013-05-22 四川省川眉芒硝有限责任公司 一种含二甲基硅油的医药芒硝口服液制造工艺
NZ704014A (en) 2012-07-27 2017-10-27 Redhill Biopharma Ltd Formulations and methods of manufacturing formulations for use in colonic evacuation
SG10201702005VA (en) 2012-09-11 2017-04-27 Norgine Bv Compositions comprising peg and ascorbate
US20140087007A1 (en) * 2012-09-27 2014-03-27 Braintree Laboratories, Inc. Bowel cleansing preparations
CN103405640B (zh) * 2013-08-19 2015-08-26 姜春杰 一种用于晚期妊娠引产术前的清肠颗粒制备方法
KR101659746B1 (ko) 2014-01-28 2016-09-26 주식회사한국파마 황산염을 함유하는 장관 하제 조성물 및 이의 제조 방법
MX2016014230A (es) 2014-04-29 2017-05-03 Colonaryconcepts Llc Alimentos, sistemas, metodos y kits para proporcionar reemplazo de electrolitos.
EP3191105A4 (en) * 2014-09-12 2018-05-02 Braintree Laboratories, Inc. Sulfate salt solution laxative compositions and methods of use thereof
KR102091852B1 (ko) 2015-03-02 2020-03-23 코로나리콘셉츠 엘엘씨 Peg 대사산물 및 peg 분해 생성물 검정을 위한 화합물 및 방법
KR102127003B1 (ko) * 2017-10-12 2020-06-25 주식회사 한국팜비오 황산염을 포함하는 대장 하제 조성물
KR102111094B1 (ko) * 2018-06-18 2020-05-14 주식회사 한국팜비오 무수황산나트륨, 황산칼륨, 무수황산마그네슘 및 시메티콘을 포함하는 장관하제 경구투여용 고형제제 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86859A (en) * 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
JP2596764B2 (ja) * 1987-11-18 1997-04-02 ルセル森下株式会社 腸管洗浄液剤
JPH0816061B2 (ja) * 1988-07-13 1996-02-21 森下ルセル株式会社 腸管洗浄液用組成物と腸管洗浄液
IT1229568B (it) * 1989-04-17 1991-09-04 Giuliani Spa Composizione farmaceutica per uso orale adatta all'impiego nel lavaggio gastro intestinale, in particolare per uso diagnostico, oppure come lassativo catartico.
US5197950A (en) 1990-07-20 1993-03-30 Clayton Ralph S Scheduled bowel management system
US5710183A (en) 1995-07-14 1998-01-20 Halow; George M. Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent
DK0858326T3 (da) 1996-05-08 2003-07-07 Craig A Aronchick Ikke-vandige colonafføringsmidler
CA2221011C (en) 1996-11-13 2003-06-24 C.B. Fleet Company, Inc. A coated sodium phosphate bowel cleanser
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
KR100529512B1 (ko) * 1997-04-18 2005-11-22 얀센 파마슈티카 엔.브이. 장 세척 촉진을 위한 5ｈｔ3 길항제의 용도
JP4092748B2 (ja) * 1997-09-05 2008-05-28 ニプロ株式会社 腸管洗浄液
AU2860500A (en) * 1999-01-29 2000-08-18 Meri Charmyne Russell Treatement of colic and gut spasm in horses and other vertebrates
AU2002335900A1 (en) * 2001-10-29 2003-05-12 Shimizu Pharmaceutical Co., Ltd. Bowel cleansing agent

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658914B2 (en) 2002-10-25 2010-02-09 Norgine Bv Colon cleansing compositions
EP2314319A1 (en) * 2002-10-25 2011-04-27 Norgine Europe BV Colon Cleansing Compositions
WO2005049049A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
CN101087593B (zh) * 2003-11-19 2013-07-17 萨利克斯药物公司 含可溶性粘合剂的结肠泻药组成物
KR101495690B1 (ko) * 2003-11-19 2015-02-25 샐릭스 파마슈티컬스 인코포레이티드 용해성 결합제를 포함하는 대장 하제 조성물
JP2007512336A (ja) * 2003-11-19 2007-05-17 サリックス ファーマシューティカルズ， インコーポレイテッド 可溶性結合剤を含む結腸下剤組成物
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
US7718197B2 (en) 2003-11-19 2010-05-18 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
EP2308476A1 (en) * 2003-11-19 2011-04-13 Inkine Pharmaceutical Company, Inc. Colonic purgative composition with soluble binding agent
AU2015221520B2 (en) * 2003-11-19 2017-06-08 Salix Pharmaceuticals, Inc. Colonic purgative composition with soluble binding agent
AU2004292428B2 (en) * 2003-11-19 2011-06-02 Salix Pharmaceuticals, Inc. Colonic purgative composition with soluble binding agent
KR101268559B1 (ko) * 2003-11-19 2013-05-31 샐릭스 파마슈티컬스 인코포레이티드 용해성 결합제를 포함하는 대장 하제 조성물
WO2005051361A1 (en) * 2003-11-19 2005-06-09 Inkine Pharmaceutical Company, Inc. Colonic purgative composition with soluble binding agent
US8507009B2 (en) 2003-11-19 2013-08-13 Salix Pharmaceuticals, Inc. Colonic purgative composition with soluble binding agent
KR101323628B1 (ko) * 2003-11-19 2013-11-01 샐릭스 파마슈티컬스 인코포레이티드 용해성 결합제를 포함하는 대장 하제 조성물
DE102005041711A1 (de) * 2005-09-01 2007-03-08 Kappstein, Ines, Prof. Dr.med. Darmspüllösung/Darmspülpulver
WO2007085676A1 (es) * 2006-01-30 2007-08-02 Laboratorios Casen-Fleet, S.L. Procedimiento de fabricación de una solución a base de polietilenglicol con electrolitos, producto obtenido y uso
US9468686B2 (en) 2009-07-30 2016-10-18 Norgine Bv Solutions comprising polyethylene glycol and electrolytes
US9919007B2 (en) 2013-03-15 2018-03-20 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
US11033498B2 (en) 2017-08-04 2021-06-15 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
US11638697B2 (en) 2017-08-04 2023-05-02 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
US12239659B2 (en) 2023-06-15 2025-03-04 Braintree Laboratories, Inc. Methods of administering safe colon cleansing compositions
US12290529B2 (en) 2023-06-15 2025-05-06 Braintree Laboratories, Inc. Methods of administering safe colon cleansing compositions
US12433914B2 (en) 2023-06-15 2025-10-07 Braintree Laboratories, Inc. Methods of administering safe colon cleansing compositions

Also Published As

Publication number Publication date
ATE457172T1 (de) 2010-02-15
ATE528011T1 (de) 2011-10-15
US20030202957A1 (en) 2003-10-30
EP2292244A3 (en) 2011-07-06
BE2013C049I2 (enExample) 2022-08-09
WO2003092589A3 (en) 2004-02-05
EP1499331B1 (en) 2010-02-10
ES2340920T3 (es) 2010-06-11
EP2233147A1 (en) 2010-09-29
PT2233147E (pt) 2012-01-12
DE60331220D1 (de) 2010-03-25
EP1499331A2 (en) 2005-01-26
SI2292244T1 (sl) 2014-01-31
US6946149B2 (en) 2005-09-20
CY1112522T1 (el) 2015-12-09
EP2292244A2 (en) 2011-03-09
PT2292244E (pt) 2014-01-14
HK1154492A1 (en) 2012-04-27
FR13C0055I1 (fr) 2013-11-01
HK1148935A1 (en) 2011-09-23
EP2233147B1 (en) 2011-10-12
CY1110011T1 (el) 2015-01-14
DK2233147T3 (da) 2012-02-06
ES2441890T3 (es) 2014-02-06
DK2292244T3 (da) 2014-01-13
SI1499331T1 (sl) 2010-07-30
ES2375446T3 (es) 2012-02-29
DK1499331T3 (da) 2010-05-31
EP1499331A4 (en) 2007-04-18
AU2003231160B2 (en) 2009-01-22
PT1499331E (pt) 2010-05-11
FR13C0055I2 (fr) 2014-11-07
EP2292244B1 (en) 2013-10-09
JP2005530743A (ja) 2005-10-13
SI2233147T1 (sl) 2012-02-29
AU2003231160A1 (en) 2003-11-17
CA2484303A1 (en) 2003-11-13
CY1114745T1 (el) 2016-12-14
CA2484303C (en) 2014-07-15

Similar Documents

Publication Publication Date Title
AU2003231160B2 (en) Salt solution for colon cleansing
US11241404B2 (en) Method, composition and package for bowel cleansing
US20110293747A1 (en) Colon cleansing solution
JP6655391B2 (ja) Ｐｅｇとアスコルビン酸塩とを含む組成物
HK1148935B (en) Salt solution for colon cleansing
HK1154492B (en) Salt solution for colon cleansing

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2484303

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004500774

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003724291

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003231160

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2003724291

Country of ref document: EP